Indirect Impact of Ten-valent Pneumococcal Conjugate Vaccine Program on Reducing Antimicrobial Use and Tympanostomy Tube Placements in Finland
- PMID: 32412982
- DOI: 10.1097/INF.0000000000002696
Indirect Impact of Ten-valent Pneumococcal Conjugate Vaccine Program on Reducing Antimicrobial Use and Tympanostomy Tube Placements in Finland
Abstract
Background: Acute otitis media (AOM) is the most common reason for antimicrobial use, and tympanostomy tube placement (TTP) is the most common reason for surgery requiring general anesthesia in children. Ten-valent pneumococcal conjugate vaccine (PCV10) was introduced in Finland in 2010 for infants. We evaluated the indirect impact of PCV10 on these surrogate otitis outcomes in unvaccinated children.
Methods: Using before-after design, unvaccinated children ineligible for National Vaccination Program (born January 2006 to May 2010) were followed-up during 2012-2016 (target cohort, age 1.5-7 years). The target cohort was compared with an age- and season-matched unvaccinated reference cohort (born January 2000 to May 2004) during 2006-2010. Antimicrobial purchase data were obtained from the Social Insurance Institution of Finland benefits register. We assessed the relative reduction by generalized Cox regression for outpatient purchases of antibiotics recommended for treatment of AOM in the Finnish guidelines. Data on all TTP procedures were obtained from national hospital discharge register and Social Insurance Institution benefits register.
Results: The rate of outpatient purchases of antimicrobials recommended for AOM was 51 in the unvaccinated reference cohort and 44/100 person-years in the unvaccinated target cohort; relative rate reduction was 14.7% [95% confidence interval: 14.0-15.3] and absolute rate reduction 7/100 person-years. The rates of TTP in the reference and target cohorts were 1.66/100 and 1.61/100 person-years, respectively. The relative rate reduction was 3.6% (0.7-6.5).
Conclusions: Antimicrobial use and TTP procedures reduced in unvaccinated children after PCV10 introduction in infants. These indirect effects contribute to the savings in health care resource use for otitis and may also help in combating antimicrobial resistance.
Similar articles
-
Impact of National Ten-Valent Pneumococcal Conjugate Vaccine Program on Reducing Antimicrobial Use and Tympanostomy Tube Placements in Finland.Pediatr Infect Dis J. 2018 Jan;37(1):97-102. doi: 10.1097/INF.0000000000001810. Pediatr Infect Dis J. 2018. PMID: 29088026
-
Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.Vaccine. 2018 Apr 5;36(15):1934-1940. doi: 10.1016/j.vaccine.2018.03.001. Epub 2018 Mar 8. Vaccine. 2018. PMID: 29526371
-
Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial.Lancet Infect Dis. 2014 Mar;14(3):205-12. doi: 10.1016/S1473-3099(13)70338-4. Epub 2013 Nov 26. Lancet Infect Dis. 2014. PMID: 24287186 Clinical Trial.
-
Brief review of the clinical effectiveness of PREVENAR against otitis media.Vaccine. 2007 Mar 22;25(13):2507-12. doi: 10.1016/j.vaccine.2006.09.027. Epub 2006 Sep 20. Vaccine. 2007. PMID: 17011085 Review.
-
The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review.Expert Rev Vaccines. 2019 Oct;18(10):1069-1089. doi: 10.1080/14760584.2019.1676155. Epub 2019 Oct 22. Expert Rev Vaccines. 2019. PMID: 31585049
Cited by
-
Otitis media sequelae and hearing in adolescence after administration of an 11-valent conjugate pneumococcal vaccine in infancy: a prospective cohort study with long-term follow-up of the ARIVAC trial.Lancet Child Adolesc Health. 2024 Sep;8(9):647-655. doi: 10.1016/S2352-4642(24)00128-7. Epub 2024 Jul 31. Lancet Child Adolesc Health. 2024. PMID: 39096922 Free PMC article. Clinical Trial.
-
ISOM 2023 Research Panel 5: Interventions- Vaccines and prevention, medical and surgical treatment, and impact of COVID-19 pandemic.Int J Pediatr Otorhinolaryngol. 2024 Jan;176:111782. doi: 10.1016/j.ijporl.2023.111782. Epub 2023 Nov 13. Int J Pediatr Otorhinolaryngol. 2024. PMID: 38000342 Free PMC article. Review.
-
Vaccination to Reduce Antimicrobial Resistance Burden-Data Gaps and Future Research.Clin Infect Dis. 2023 Dec 20;77(Suppl 7):S597-S607. doi: 10.1093/cid/ciad562. Clin Infect Dis. 2023. PMID: 38118013 Free PMC article.
References
-
- Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187–195.
-
- Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381:214–222.
-
- Palmu AA, Jokinen J, Nieminen H, et al. Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial. Vaccine. 2018;36:1816–1822.
-
- Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA. 2009;302:758–766.
-
- Cullen KA, Hall MJ, Golosinskiy A. Ambulatory surgery in the United States, 2006. Natl Health Stat Report. 2009;11:1–25.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical